$7.91 +0.31 (4.08%) ChemoCentryx Inc - NASDAQ

Dec. 9, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 7.91
Trade Time: Dec 09 04:00 PM Eastern Daylight Time
Change: +0.31 (4.08%)
Prev Close: 7.60
Open: 7.68
Bid: 7.90
Ask: 7.91
  1. No results found.
  1. Market Reversal In Biotech But Healthcare Stocks Are Still Muddled

    TalkMarkets | Nov. 29, 2016 | 22:56PM EST
  2. ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168

    Benzinga | Jan. 6, 2016 | 07:00AM EST
  3. Wednesday's After-Hours Movers: 10 Stocks To Watch

    Benzinga | Sep. 24, 2015 | 07:10AM EST
  4. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

    Benzinga | Jan. 13, 2015 | 10:58AM EST
  5. Biggest Gainers From Friday, December 12, 2014

    Benzinga | Dec. 12, 2014 | 16:31PM EST
  6. Mid-Morning Market Update: Markets Open Lower; Adobe Earnings Top Expectations

    Benzinga | Dec. 12, 2014 | 11:34AM EST
  7. ChemoCentryx Up 70%, Lead Drug Meets Phase II Objective

    Benzinga | Dec. 12, 2014 | 10:37AM EST
  8. Morning Market Movers

    Benzinga | Dec. 12, 2014 | 09:42AM EST
  9. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 12, 2014 | 08:07AM EST
  10. ChemoCentryx Reports Positive Phase II Diabetic

    Benzinga | Dec. 12, 2014 | 06:33AM EST
  11. Three Attractively Priced Small Cap Biotech Stocks

    GuruFocus | Nov. 5, 2014 | 12:45PM EST
  12. ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease

    Benzinga | Oct. 20, 2014 | 07:32AM EST
  13. ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology

    Benzinga | Mar. 27, 2014 | 07:31AM EST
  14. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 4, 2013 | 08:11AM EST
  15. ChemoCentryx Will Regain Global Rights for Vercirnon from Glaxo, Will Assess If Drug Maintains Remission in Crohn's Disease

    Benzinga | Sep. 18, 2013 | 07:39AM EST
Trading Center